Biora Therapeutics Inc (BIOR)vsNovartis AG ADR (NVS)
BIOR
Biora Therapeutics Inc
$0.22
0.00%
HEALTHCARE · Cap: $994,990
NVS
Novartis AG ADR
$158.44
-1.45%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6592109% more annual revenue ($56.69B vs $860,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. BIOR trades at a lower P/E of 0.6x. NVS earns a higher WallStSmart Score of 51/100 (C-).
BIOR
Hold38
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIOR.
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.44
$65.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Revenue surging 15800.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOR
The strongest argument for BIOR centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 15800.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : BIOR
The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
BIOR profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
BIOR carries more volatility with a beta of 1.28 — expect wider price swings.
BIOR is growing revenue faster at 15800.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 38/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biora Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?